WhatsApp
backNews Article

Piramal Pharma to Acquire Remaining 26% Stake in Yapan Bio, Boosting Ownership to Full Control

Final acquisition terms and effective transfer date of shares are yet to be finalized following Board committee approval

Piramal Pharma Limited has approved exercising its call option to acquire the remaining 26% equity stake in its subsidiary, Yapan Bio Private Limited. The acquisition will make Yapan a wholly owned subsidiary, with final terms and effective date pending. Yapan specializes in vaccine and biologics manufacturing services.

20 hours ago|PPLPHARMA+0.29%
Piramal Pharma Limited543635PPLPHARMAAcquisition / Amalgamation / Merger / Demerger

Piramal Pharma Limited

Acquisition / Amalgamation / Merger / Demerger

Piramal Pharma Limited’s Board committee has approved exercising its call option to acquire the remaining 26% equity stake in its subsidiary Yapan Bio Private Limited, aiming to increase its ownership from 74% to 100%.

The acquisition will make Yapan Bio a wholly owned subsidiary of Piramal Pharma Limited.

Yapan Bio Private Limited operates as a contract development and manufacturing organization (CDMO) providing process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics.

Post-approval, the company is engaged in discussions with Yapan’s existing shareholders to finalize the acquisition consideration and effective date for share transfer.

The final terms and completion of the transaction will be disclosed as per SEBI Listing Regulations.

The transaction consolidates Piramal Pharma's control over Yapan Bio, strengthening its presence in vaccine and biologics manufacturing services.

Highlights

  • Piramal Pharma currently holds 74% equity in Yapan Bio.
  • The company plans to acquire the remaining 26% stake via a call option.
  • Yapan Bio specializes in vaccine and biologics process development and Phase I/II GMP manufacturing.
  • Final transaction terms, including consideration and transfer date, are still being finalized.
  • Completion disclosures will be made following execution of definitive documentation.

Key Data Snapshot

Current shareholding in Yapan Bio74%
Stake to be acquired under call option26%
Resulting ownership in Yapan Bio after acquisition100%
Date of announcement18th November, 2026

What happened

  • Piramal Pharma’s Board committee approved exercising its call option to acquire the remaining 26% equity stake in Yapan Bio Private Limited.
  • This acquisition will increase Piramal Pharma's ownership in Yapan Bio from 74% to 100%.
  • Yapan Bio will become a wholly owned subsidiary upon completion of the transaction.

Key details

  • Final terms including acquisition consideration and effective date of share transfer are still being negotiated.
  • Disclosures as per SEBI regulations will follow upon completion of the transaction.
  • Piramal Pharma is currently engaged in discussions with existing Yapan Bio shareholders to finalize transaction details.

Background and context

  • Yapan Bio Private Limited is a Contract Development and Manufacturing Organization (CDMO).
  • Specializes in process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics.
  • The acquisition aligns with Piramal Pharma’s strategic consolidation of its subsidiary.

More News on Acquisition / Amalgamation / Merger / Demerger

View all

Latest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.

View all news
Piramal Pharma to Acquire Remaining 26% Stake in Yapan | Stockk News